Prime Medicine
PRME
66 hedge funds and large institutions have $768M invested in Prime Medicine in 2022 Q4 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
42.51% more ownership
Funds ownership: 0% → 42.51% (+43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$240M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$153M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$43M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$39.9M |
| 5 |
MM
MWG Management
Road Town, Tortola,
British Virgin Islands
|
+$33.2M |
Top Sellers
PRME Hedge Fund Activity: Q4 2022 in Review
66 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q4 2022, worth a combined $768M.
Buyers outnumbered sellers: 66 funds opened new PRME positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Alphabet Inc, opening a new position worth an estimated $240M.
- 66 institutional investors held Prime Medicine (PRME) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $768M of Prime Medicine stock for Q4 2022.
- 66 funds opened new Prime Medicine positions in Q4 2022 and 0 closed out, a net change of +66 holders.
- The largest Prime Medicine buyer in Q4 2022 was Alphabet Inc, an estimated $240M added.
Based on aggregated 13F filings for Q4 2022.